scholarly journals Bronchoalveolar lavage of ventilator‐associated pneumonia patients for antibiotic resistance and susceptibility test

2022 ◽  
Vol 5 (1) ◽  
Author(s):  
Mojtaba Ahmadinejad ◽  
Sanaz Mohammadzadeh ◽  
Haleh Pak ◽  
Seyedehhamideh Hashemiyazdi ◽  
Ali Soltanian ◽  
...  
Author(s):  
Hairiah Asty

Ventilator associated pneumonia (VAP) is the most common hospital infection in ICU. Proper and prompt diagnosis and treatment with adequate antibiotics can reduce the high mortality rate, and prevent complications and antibiotic resistance. Invasive methods, such as bronchoalveolar lavage can make a more accurate diagnosis and help with the choice of antibiotics, but require lung experts. While non-invasive methods, such as endotracheal aspirate can be done faster with less complications. The aim of the study was to determine the pattern of bacterial and bacterial sensitivity to bronchoalveolar lavage and endotracheal fluid. This was an observational study with cross-sectional approaches performed at the Intensive Care Unit of RSUP H. Adam Malik Medan, in August 2017 - February 2018. The sample of  23 patients  who met the criteria and was suspected with VAP was carried out by taking endotracheal aspirate and bronchoalveolar lavage. The samples obtained were culture and sensitivity test using BD Phoenix. There was bacteria pattern had compatibility at moderate levels and there was sensitivity and antibiotic resistance were not significantly different from bronchoalveolar cultures and endotracheal aspirate cultures. Endotracheal aspirate culture has a sensitivity of 78.9% and a specificity of  75% for diagnose VAP. Information on the identification of bacteria and sensitivity testing in patients with suspected VAP is required using appropriate sampling techniques. There were no significant differences between bronchoalveolar lavage culture and endotracheal aspirate culture to diagnosing VAP. Endotracheal aspirate culture is a non invasive diagnostic tool that can be used as an alternative diagnostic tool in patients with suspected VAP.


2000 ◽  
Vol 16 (6) ◽  
pp. 1152-1157 ◽  
Author(s):  
R.P. Baughman ◽  
R.E. Spencer ◽  
B.O. Kleykamp ◽  
M.C. Rashkin ◽  
M.m Douthit

Critical Care ◽  
10.1186/cc817 ◽  
2000 ◽  
Vol 4 (Suppl 1) ◽  
pp. P97
Author(s):  
A Koroneos ◽  
I Kalomenidis ◽  
F Moraitou ◽  
P Polakis ◽  
S Papanikolaou ◽  
...  

2005 ◽  
Vol 59 (4) ◽  
pp. 891-896 ◽  
Author(s):  
Matthew M. Mondi ◽  
Michael C. Chang ◽  
David L. Bowton ◽  
Patrick D. Kilgo ◽  
J Wayne Meredith ◽  
...  

Critical Care ◽  
2011 ◽  
Vol 15 (S1) ◽  
Author(s):  
V Grover ◽  
P Kelleher ◽  
D Henderson ◽  
P Pantelidis ◽  
F Gotch ◽  
...  

Antibiotics ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 26 ◽  
Author(s):  
Ilaria Maria Saracino ◽  
Giulia Fiorini ◽  
Angelo Zullo ◽  
Matteo Pavoni ◽  
Laura Saccomanno ◽  
...  

Background and aims: the increasing prevalence of strains resistant to antimicrobial agents is a critical issue for the management of Helicobacter pylori infection. This study aimed to evaluate, in Italian naïve patients, H. pylori antibiotic resistance trends and their potential predictive factors during the last decade. Methods: consecutive Italian naïve H. pylori positive patients, referred from General Practitioners to our Unit from January 2009 to January 2019 to perform an upper gastrointestinal endoscopy (UGIE), were considered. Each patient underwent 13C-urea breath test (13C-UBT) and UGIE with multiple biopsies to perform rapid urease test (RUT), culture/susceptibility test (vs. clarithromycin, metronidazole, levofloxacin), and histopathological examination. H. pylori status was assessed through CRM (composite reference method: at least two tests positive or only culture positive). Results: between 2009 and 2014, 1763 patients were diagnosed as H. pylori positive, 907 were naïve with antibiogram available. Between 2015 and 2019, 1415 patients were diagnosed as H. pylori positive, antibiotic susceptibility test was available in 739 naïve patients. H. pylori primary antibiotic resistance rates in the first and second five-year period were, respectively, clarithromycin 30.2% (95% CI 27.2–33.3), 37.8% (95% CI 34.2–41.4); metronidazole 33.3% (95% CI 30.2–36.5), 33.6% (95% CI 30.2–37.1); levofloxacin 25.6% (95% CI 22.8–28.5), 33.8% (95% CI 37.4–47.4), double resistance clarithromycin-metronidazole 18.9% (95% CI 16.4–21.6), 20.7% (95% CI 17.8–23.8). The increase of the resistance rates to clarithromycin and levofloxacin in naïve patients was statistically significant (p < 0.05). Although eradication rates for sequential therapy in the 10 years considered were 93.4% (95% CI 92–94.6) and 87.5% (95% CI 85.7–89) at per-protocol (PP) and intention-to-treat (ITT) analysis, respectively, they showed a significant decrease in the second five-year period. Conclusions: this data highlights an increase in primary H. pylori antibiotic resistance and strongly suggests the importance of drug susceptibility testing also in naïve patients.


Sign in / Sign up

Export Citation Format

Share Document